Individualising Therapy to Minimize Bacterial Multidrug Resistance

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Drugs

• Publication date

  2018-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-018-0891-9PMID 29569104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model

  2018cited by this paper
• MIC-based dose adjustment: facts and fables

  2018cited by this paper
• Re: 'Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?' Pharmacokinetic/pharmacodynamic considerations.

  2018cited by this paper
• A 10‐Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital‐wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?

  2017cited by this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

  2017cited by this paper
• Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

  2017cited by this paper
• Determining &bgr;-lactam exposure threshold to suppress resistance development in Gram-negative bacteria

  2017cited by this paper
• Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae

  2017cited by this paper
• Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies.

  2017cited by this paper
• Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact

  2017cited by this paper
• Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

  2017cited by this paper
• Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?

  2017cited by this paper
• Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections

  2017cited by this paper
• Post-stroke dementia – a comprehensive review

  2017cited by this paper
• Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

  2017cited by this paper
• Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis

  2017cited by this paper
• Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes

  2017cited by this paper
• In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae

  2017cited by this paper
• Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.

  2017cited by this paper
• Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus

  2017cited by this paper
• Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration

  2017cited by this paper
• Procalcitonin-guided diagnosis and antibiotic stewardship revisited

  2017cited by this paper
• Biomarker-guided antibiotic therapy-strengths and limitations.

  2017cited by this paper
• Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies.

  2016cited by this paper
• Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

  2016cited by this paper
• Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

  2016cited by this paper
• Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa

  2016cited by this paper
• Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.

  2016cited by this paper
• Absence of obvious link between supra-therapeutic serum levels of β lactams and clinical toxicity in ICU patients with acute renal failure treated with intermittent hemodialysis

  2016cited by this paper
• Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

  2016cited by this paper
• Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance

  2016cited by this paper
• Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis

  2016cited by this paper
• Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?

  2016cited by this paper
• Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

  2016cited by this paper
• Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria

  2016cited by this paper
• Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling

  2016cited by this paper
• Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug AdministrationApproved Antibiotics, 20102015

  2016cited by this paper
• Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?

  2016cited by this paper
• Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii

  2016cited by this paper
• Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii

  2016cited by this paper
• Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock

  2016cited by this paper
• Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy

  2016cited by this paper
• Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

  2016cited by this paper
• Therapeutic drug monitoring of anti-infective agents in critically ill patients

  2016cited by this paper
• Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.

  2016cited by this paper
• Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

  2016cited by this paper
• Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.

  2016cited by this paper
• Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

  2016cited by this paper
• Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.

  2016cited by this paper
• Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review.

  2016cited by this paper
• Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

  2015cited by this paper
• Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

  2015cited by this paper
• Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.

  2015cited by this paper
• Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring

  2015cited by this paper
• Risk factors for acquisition of multidrug-resistant bacteria in patients with anastomotic leakage after colorectal cancer surgery

  2015cited by this paper
• A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics

  2015cited by this paper
• Population Pharmacokinetics of Fosfomycin in Critically Ill Patients

  2015cited by this paper
• Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion.

  2015cited by this paper
• Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

  2015cited by this paper
• Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill

  2015cited by this paper
• A Randomized Trial of Loading Vancomycin in the Emergency Department

  2015cited by this paper
• Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.

  2015cited by this paper
• Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance

  2015cited by this paper
• Trial of short-course antimicrobial therapy for intraabdominal infection.

  2015cited by this paper
• Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure

  2015cited by this paper
• Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations

  2015cited by this paper
• Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii

  2015cited by this paper
• Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model

  2015cited by this paper
• Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

  2015cited by this paper
• Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.

  2015cited by this paper
• Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.

  2015cited by this paper
• Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study

  2015cited by this paper
• Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii

  2014cited by this paper
• Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.

  2014cited by this paper
• Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

  2014cited by this paper
• Evaluation of Meropenem Regimens Suppressing Emergence of Resistance in Acinetobacter baumannii with Human Simulated Exposure in an In Vitro Intravenous-Infusion Hollow-Fiber Infection Model

  2014cited by this paper
• DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

  2014cited by this paper
• Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

  2014cited by this paper
• Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

  2014cited by this paper
• Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.

  2014cited by this paper
• Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

  2014cited by this paper
• Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model

  2014cited by this paper
• How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?

  2014cited by this paper
• Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study

  2014cited by this paper
• Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment

  2014cited by this paper
• Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

  2014cited by this paper
• A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.

  2014cited by this paper
• Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

  2013cited by this paper
• Pattern of Brain Injury in the Acute Setting of Human Septic Shock

  2013cited by this paper
• Gram‐negative resistance: can we combat the coming of a new “Red Plague”?

  2013cited by this paper
• Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis.

  2013cited by this paper
• Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis

  2013cited by this paper
• Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis

  2013cited by this paper
• Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial*

  2013cited by this paper
• Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa

  2013cited by this paper
• Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105 and 107 CFU Injected into Opposite Thighs of Neutropenic Mice

  2013cited by this paper
• Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.

  2013cited by this paper
• The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.

  2013cited by this paper
• Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

  2013cited by this paper
• Resuscitative strategies in traumatic hemorrhagic shock

  2013cited by this paper

• Optimising Meropenem and Piperacillin Dosing in Patients Undergoing Extracorporeal Membrane Oxygenation Without Renal Dysfunction (MEPIMEX)

  2025cites this paper
• A prospective cohort feasibility study of real-time beta-lactam antimicrobial therapeutic drug monitoring in critically ill patients with lower respiratory infection: The TDM-TIME study

  2025cites this paper
• Oral Infection Therapeutics Reimagined: Transformative Drug Delivery Technologies and Beyond

  2025cites this paper
• Pharmacokinetic/pharmacodynamic targets of ß-lactams associated with bacterial killing and suppression of the resistance emergence in the hollow fiber infection model: a systematic review.

  2025cites this paper
• Prevalence of on time administration of carbapenem and its impact on PK/PD target attainment in hospitalized patients: a multicenter retrospective study

  2025cites this paper
• Emerging Trends in Designing the Dendrimer-Based Drug Delivery for Antineoplastic Therapies.

  2025cites this paper
• Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem

  2024cites this paper
• Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial

  2024cites this paper
• Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis

  2024cites this paper
• Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections

  2023cites this paper
• Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review

  2023cites this paper
• Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling

  2023cites this paper
• Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.

  2023cites this paper
• Systems Biomarkers, Artificial Intelligence, and One Health Vision Can Help Fight Antimicrobial Resistance

  2023cites this paper
• ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs

  2023cites this paper
• Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time

  2023cites this paper
• Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections

  2023cites this paper
• Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

  2022cites this paper
• Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia

  2022cites this paper
• Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants.

  2022cites this paper
• Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability

  2022cites this paper
• Presence and antimicrobial resistance profiles of Escherichia coli, Enterococcusspp. and Salmonellasp. in 12 species of Australian shorebirds and terns

  2022cites this paper
• A systematic review of the effect of therapeutic drug monitoring on patient health outcomes during treatment with penicillins

  2022cites this paper
• Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection

  2022cites this paper
• Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).

  2022cites this paper
• Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis

  2021cites this paper
• Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.

  2021cites this paper
• The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance

  2021cites this paper
• Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients

  2021cites this paper
• Rationaler Antibiotikaeinsatz in der Gefäßchirurgie

  2021cites this paper
• Antibiotics Therapy in the Multi-Resistant Patient.

  2021cites this paper
• The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials

  2021cites this paper
• Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review.

  2021cites this paper
• Optimizing Antimicrobial Drug Dosing in Critically Ill Patients

  2021cites this paper
• Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections

  2021cites this paper
• Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient.

  2021cites this paper
• Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections

  2021influential citation
• Anti-bacterial Agents

  2021cites this paper
• Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation

  2020influential citation
• Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review.

  2020cites this paper
• The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin

  2020cites this paper
• Update on Susceptibility Testing: Genotypic and Phenotypic Methods.

  2020cites this paper
• Antibiotikadosering – teori og praksis

  2020cites this paper
• Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains

  2020cites this paper
• Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass

  2020cites this paper
• Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.

  2020cites this paper
• Therapeutic drug monitoring of β-lactam antibiotics in the ICU

  2020cites this paper
• Personalised antimicrobial dosing: standing on the shoulders of giants.

  2020cites this paper
• Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis

  2019cites this paper
• Individualized antibiotic therapy in the treatment of severe infections

  2019cites this paper
• Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia

  2019cites this paper
• How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients

  2018cites this paper
• Impact of combined antibiotic treatment on multidrug-resistant bacteria emergence after postoperative intra-abdominal infections

  2018cites this paper